罗沙司他在治疗慢性肾脏病所致的贫血及其他适应证中的应用进展  

Progress in the Application of Roxadustat in the Treatment of Anemia and other Indications Caused by Chronic Kidney Disease

作　　者：刘倩倩[1] 李昕萌 刘云启[1] LIU Qianqian;LI Xinmeng;LIU Yunqi(Department of Nephrology,Affiliated Hospital of Binzhou Medical University,Binzhou 256603,China;不详)

机构地区：[1]滨州医学院附属医院肾内科,山东滨州256603

出　　处：《中国医学创新》2025年第5期175-179,共5页Medical Innovation of China

摘　　要：罗沙司他属于缺氧诱导因子脯氨酸羟化酶抑制剂(hypoxia-inducible factor-prolyl hydoxylase inhibitors,HIF-PHIs),作为一种新型的口服制剂,可有效改善透析及非透析依赖性慢性肾脏病(chronic kidney disease,CKD)患者的贫血症状,其疗效并不逊于传统的治疗方式。罗沙司他的广泛应用不仅体现在CKD所致贫血的治疗上,而且还发现在移植后贫血(posttransplant anemia,PTA)及心血管保护等适应证上有新的治疗作用,这为其他相关疾病的治疗提供了新的可能与希望。此外,罗沙司他的安全性及不良反应方面也值得关注。本文旨在通过归纳罗沙司他在CKD所致贫血及对其他适应证的治疗方面展开描述,以期为临床应用提供参考。Roxadustat is a hypoxia-inducible factor-prolyl hydoxylase inhibitors(HIF-PHIs),which is a new oral formulation.It can effectively improve the anemia symptoms of dialysis and non-dialysis dependent chronic kidney disease(CKD)patients,and its curative effect is not inferior to the traditional treatment.The wide application of Roxadustat is not only reflected in the treatment of anemia caused by CKD,but also found to have new therapeutic effects in indications such as posttransplant anemia(PTA)and cardiovascular protection,which provides new possibilities and hopes for the treatment of other related diseases.In addition,the safety and adverse reactions of Roxadustat are also of concern.The purpose of this article is to describe Roxadustat in the treatment of anemia caused by CKD and other indications,in order to provide reference for clinical application.

关 键 词：罗沙司他 慢性肾脏病 缺氧诱导因子脯氨酸羟化酶抑制剂 贫血 移植后贫血 

分 类 号：R692[医药卫生—泌尿科学] R556[医药卫生—外科学]